The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. has announced the successful closing of its oversubscribed follow-on equity offering.
The proceeds are set to accelerate the development and manufacturing of the company’s lead candidate, ficerafusp alfa, with an added focus on a less frequent dosing option. The new funding will also bolster Bicara Therapeutics Inc.'s commercial and regulatory readiness activities in the U.S., positioning the company for upcoming milestones. Specific financing terms and investors were not detailed in the announcement.